Clinical Trial Update: A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Sunitinib in patients with metastatic or recurrent thymic carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Thymic Carcinoma | Phase 2 | Status: COMPLETED